Clinical Trial Update: Cadonilimab(AK104) Plus Concurrent Chemoradiotherapy in Patients With Locally Advanced, Unresectable, Stage III NSCLC [Phase 2]

View source ↗

Summary

Phase 2 study evaluating Cadonilimab (AK104) with concurrent chemoradiotherapy in locally advanced, unresectable stage III non-small cell lung cancer; the trial…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Cadonilimab

Snippet

Sponsor: Fudan University | Conditions: NSCLC, Locally Advanced Lung Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING